Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis — Intuitive Venture Partners | Venture Capital Firms NYC | Investment Bank New York City

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis

Intuitive Venture PartnersJuly 28, 20252025, entera bio